Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.3K
Peripherally and Centrally Acting Muscle Relaxants: A Comparison01:09

Peripherally and Centrally Acting Muscle Relaxants: A Comparison

4.0K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
4.0K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

694
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
694
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

840
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
840
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

586
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
586
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.1K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of Cognitive Reserve on Age at Symptom Onset and Cognitive Decline in Individuals With Dominantly Inherited Alzheimer Disease.

Neurology·2026
Same author

15 years of longitudinal genetic, clinical, cognitive, imaging, and biochemical measures in DIAN.

NPJ dementia·2026
Same author

Alzheimer's Imaging Consortium.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Public Health.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Validation of a MIND diet screener in older adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Related Experiment Video

Updated: Nov 9, 2025

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

1.1K

Update on rivastigmine.

Martin R Farlow1

  • 1Department of Neurology, Indiana University School of Medicine, Indianapolis, IN 46202-5111, USA. mfarlow@iupui.edu

The Neurologist
|November 1, 2003
PubMed
Summary

Rivastigmine effectively treats cognitive and behavioral symptoms in Alzheimer

Area of Science:

  • Pharmacology
  • Neuroscience
  • Geriatrics

Background:

  • Rivastigmine is a carbamate drug that inhibits acetylcholinesterase and butyrylcholinesterase.
  • Butyrylcholinesterase levels increase with Alzheimer disease progression, making its inhibition crucial.
  • Rivastigmine metabolism occurs at the synapse, not the liver, minimizing drug-drug interactions.

Purpose of the Study:

  • To evaluate the efficacy of rivastigmine in managing cognitive and behavioral symptoms.
  • To assess rivastigmine's impact on daily living, behavior, cognition, and global functioning.
  • To explore rivastigmine's potential benefits in various dementia subtypes.

Main Methods:

  • Analysis of 4 large double-blind, placebo-controlled multicenter clinical trials in mild to moderate Alzheimer disease.

More Related Videos

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.0K
MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

14.4K

Related Experiment Videos

Last Updated: Nov 9, 2025

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models
04:30

Author Spotlight: Translational Applications of Stimulated SFEMG in Rodent Models

Published on: March 8, 2024

1.1K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.0K
MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

14.4K
  • Review of studies on rivastigmine in diffuse Lewy body disease, severe Alzheimer disease, Parkinson dementia, and subcortical dementia.
  • Examination of dosage titration strategies and adverse effect profiles.

    • Main Results:

    • Rivastigmine therapy, with appropriate dosage titration, improves daily living, behavior, cognition, and global functioning in Alzheimer disease.
    • Slower, monthly dosage increases minimize adverse effects like nausea, vomiting, and diarrhea.
    • Effective in reducing psychiatric symptoms and cognitive deficits in diffuse Lewy body disease and shows promise in other dementia types.

    Conclusions:

    • Rivastigmine is a proven therapeutic agent for Alzheimer disease and diffuse Lewy body disease.
    • It demonstrates potential benefits for vascular dementia and Parkinson dementia.
    • Rivastigmine may delay disease progression with no observed withdrawal effects.